Accuray touts 2 radiation therapy studies

Radiation oncology firm Accuray is touting results from two studies that investigate...Read more on AuntMinnie.comRelated Reading: Accuray posts mixed Q2 results Accuray touts CyberKnife study results Accuray makes 1st Radixact install in Utah Accuray, RaySearch treat 1st patients in Asia-Pacific Accuray appoints former GE manager as CCO
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Authors: Lin M, Li Y, Qin S, Jiao Y, Hua F Abstract Ubiquitin-like modifier-activating enzyme 7 (UBA7) is a specific E1-like ubiquitin-activating enzyme involved in interferon-stimulated gene 15 (ISG15) conjugation. UBA7 expression has been reported to be notably decreased in lung cancer. The present study aimed to investigate the changes in UBA7 expression in breast cancer and the association between UBA7 expression and clinical characteristics, and to elucidate the diagnostic and prognostic significance of UBA7 in breast cancer. The clinical data and RNA-sequencing expression values of 1,104 patients with breast ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Abstract Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome. Clear cell chondrosarcoma (CCCS) is a rare variant of chondrosarcoma. Here, we report a case of CCCS in the talus occurring in a patient with VHL disease. A 32-year-old man presented with ankle pain for 2 years. MRI revealed a 4.2 cm mass in the talus, and needle biopsy was performed. The patient underwent curettage but the final diagnosis was CCCS. Adjuvant radiation therapy was performed without additional talectomy and the patient was alive without recurrence for a follow-up period of 2 years. To our knowledge, this is t...
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research
CONCLUSION: Induction chemotherapy with Cisplatin and Docetaxel is a promising regimen with good response and favorable toxicity profile and can be considered as a potentially effective outpatient regimen for locally advanced squamous cell carcinoma of head and neck. PMID: 32212813 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
CONCLUSION: Once weekly low dose cisplatin treatment showed lower acute toxicity and a better compliance compared to once every 3 weeks high dose cisplatin treatment at the expense of a lower loco-regional control. PMID: 32212810 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Intraoperative radiation therapy is an emerging option for adjuvant therapy for early stage breast cancer, although it is not currently considered standard of care in the United States. We applied time-driven activity-based costing to compare two alternative methods of breast intraoperative radiation therapy, including treatment similar to the techniques employed in the TARGIT-A clinical trial and a novel version with CT-guidance and high-dose-rate (HRD) brachytherapy.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Glioblastoma Interventions:   Drug: CC-90010;   Drug: Temozolomide Sponsor:   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Symptom Monitoring;   Radiation Therapy Intervention:   Other: Noona Software Sponsors:   Washington University School of Medicine;   Varian Medical Systems Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glioblastoma Interventions:   Drug: CC-90010;   Drug: Temozolomide Sponsor:   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Symptom Monitoring;   Radiation Therapy Intervention:   Other: Noona Software Sponsors:   Washington University School of Medicine;   Varian Medical Systems Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glioblastoma Interventions:   Drug: CC-90010;   Drug: Temozolomide Sponsor:   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Radiation Therapy | Radiology | Study